Catheter PrecisionVTAK
VTAK
About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Employees: 14
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.61% less ownership
Funds ownership: 9.36% [Q2] → 5.75% (-3.61%) [Q3]
21% less funds holding
Funds holding: 14 [Q2] → 11 (-3) [Q3]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
88% less capital invested
Capital invested by funds: $415K [Q2] → $50.8K (-$364K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for VTAK.
Financial journalist opinion
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces Initial LockeT Purchase From Montefiore Medical Center
FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the New York City area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the NYC region.
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter include: Commercial Endeavors Marie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN
FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal. As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29.
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds
FORT MILL, SC / ACCESSWIRE / October 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series H and Series I warrants (collectively, the "Existing Warrants") to purchase up to an aggregate of 5,347,981 shares of the Company's stock at a reduced exercise price of $0.70 for total gross proceeds of approximately $3.7 million. An additional $1,185,000 of gross proceeds were received through the exercise of warrants over the last week in accordance with their original terms.
Neutral
Accesswire
1 month ago
Catheter Precision to Attend Society for Cardiac Robotic Navigation With New Clinical Data Presented on October 28 – 29
FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there will be two presentations showcasing the VIVO technology at the International Society for Cardiac Robotic Navigation Meeting (SCRN) October 28-29 in Lisbon, Portugal. The 2024 program highlights VIVO in the presentations.
Neutral
Accesswire
2 months ago
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024 issue of HeartRhythm Case Reports. This recent publication focuses on a patient procedure in which a novel, non-invasive ablation technique known as stereotactic radioablation ("STAR") was used.
Neutral
Accesswire
2 months ago
Catheter Precision to Attend the International Symposium on Catheter Ablation Techniques
FORT MILL, SC / ACCESSWIRE / October 15, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16 - 18 in Paris, France. ISCAT is a biannual European meeting that focuses on new and emerging catheter ablation technologies, techniques, and study data for both atrial and ventricular arrhythmias.
Neutral
Accesswire
2 months ago
Catheter Precision Scheduled to Attend the International Ventricular Tachycardia (VT) Symposium October 11 - 12 in New York City
FORT MILL, SC / ACCESSWIRE / October 10, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 19th annual International VT Symposium on October 11 and 12 in New York City. The VT Symposium is hosted and coordinated by the Hospital at the University of Pennsylvania and Mount Sinai Hospital and focuses on new information and management strategies used for the care of ventricular arrhythmias in various disease states, including nonpharmacological therapies such as implantable devices and catheter ablation techniques.
Neutral
Accesswire
2 months ago
Catheter Precision Continues to Expand Clinical Data and Acceptance of VIVO
FORT MILL, SC / ACCESSWIRE / October 2, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a company dedicated in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced several updates for their VIVO non-invasive mapping system. Over the last 60 days and through the month of October the company has participated in several industry meetings where VIVO has been or will be highlighted.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Receives Chinese Patent for LockeT
FORT MILL, SC / ACCESSWIRE / September 24, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American), a company engaged in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced that has received notification of the issuance of its first LockeT patent in the country of China. Locket is a suture retention device used in the closure of percutaneous catheter access sites during any number of catheter procedures including electrophysiology, structural heart, and vascular surgery procedures.
Charts implemented using Lightweight Charts™